Title: Kinetic%20
1Kinetic Dynamic in Poisoning
2The Dose Makes The Poison
- What is there that is not poison? All things are
poison and nothing is without poison. Solely
the dose determines that a thing is not a poison
Philip Theophrastus Bombast von Hohenheim aka
PARACELSUS (1493-1541)
3Our Body Defines The Poison
- Things are poison
- if our body do something on it (kinetic)
- and the thing do something on us (dynamic)
4Why Do We Need To Know?
- Basic science principle
- Understanding why
- More easy to memorize stuffs
- Clinical application
- Guide our management decision
- From principle
- Help us to make tough call
- Especially in unstudied situation
5What Do We Need To Know?
- Everything , ideally but Impossible
6(No Transcript)
7In Real Life
- We are clinicians, not scientists
- Just some basic
- Relevant to our clinical practice
8ToxicoKinetic
- 1st step of toxicity
- 4 basic steps
- Absorption
- Distribution
- Metabolism
- Elimination
9Compartments
- Our body
- Compartments
- Membrane
- Special barriers
- BBB
- Placenta
10Transfer Between Compartments
- Diffusion
- Size
- Lipophilic Vs Hydrophilic
- Charge or not/pH
- Protein bound
- Follow gradient
- Active Transport
- Can against gradient
- Used up energy
- More Specific
- NaK ATPase
- G-glycoprotein
11Disclaimer PK data
- From therapeutic range data
- Few from overdose
- PK is usually different in OD situation
- We are all different
- Pharmacogenetic
12Absorption
- Route of exposure
- Ingestion
- Inhalation
- Dermal
- Bioavailability (F)
- Absorption Vs Pre-systemic elimination
- Vmax/Cmax
13Delay Absorption
- Simply not dissolve
- Full stomach
- Enteric coated, SR preparation
- Stick together
- Aspirin, Fe
- Gut slow down
- Anticholinergic
- Opioids
14Distribution
- Compartments Model
- Volume of distribution
- Protein Bound
- Redistribution
- Therapeutic drug monitoring
15Compartment Model
- One Compartment
- Two Compartment
- Digoxin, Li
- Three Compartment
- Lead
16Volume Of Distribution (Vd)
- Concentration (mg/L)
- Dose (mg) X Bioavailability
- BW (kg) X Vd (L/kg)
- Cautious on units
- Expressed in L/kg
- Small lt 1L/kg
- Stay in blood mostly
- Large gt 1Lgtkg
17Protein Bound
- Albumin others
- Saturation in overdose situation
- Displacement
- Potential interaction
- Bound-toxicants
- NOT able to pass barrier
- NOT active
- Confused the level
18Redistribution
- Equilibrium shift
- Environment of different compartments change
- Rebound
- Li after HD
- Fat loss
- Superwarfarin toxicity
19Limitation Of Drug Level
- Measure one compartment only (plasma)
- Usually not well correlated to clinical toxicity
- Time of sampling is crucial
- Usually measure the total drug
- Bounded (inactive) and Unbounded (active)
20Metabolism
- Biotransformation
- Phase I
- Phase II
- Facilitate the elimination
- Result in
- More toxic Try to block it !
- Less toxic Try to enhance it !
- Inactive metabolites
21ADH
ALDH
Methanol
Formate
Formaldehyde
FOLATE
22Metabolism Kinetic
- Zero order kinetic
- Ethanol
- 15-20 mg/dl/hr
- 1st order kinetic
- Most drugs
- T1/2
- Michaelis-Menten Kinetic
- Phenytoin
23Elimination T1/2
- 1st kinetic order only
- Five T1/2 3.125 of the initial dose
- May be different in overdose situation
- Only measure the parent compound
- Not the metabolites
- Not necessarily Duration of action
- May have active metabolites
- Mellanby Effect
- Redistributed out of target organ
24Cytochrome P450
- Polymorphism
- Major risk area for ADR, Interaction
- Important Subtypes
- 1A2
- 2C9,2C19
- 2D6
- 2E1
- 3A4
- Cimitidine
25Metabolic Pathways of Codeine Biotransformation
Gasche, Y. et al. N Engl J Med 20043512827-2831
26Elimination
- Renal
- Hepatobiliary
- recirculation
- Lung
- Sweat/hair
27Enhanced Elimination
- Alkalinization of Urine
- Haemodialysis
- Charcoal Haemoperfusion
- Exchange Transfusion
- MDAC
28Alkalinization Of Urine
- Enhanced elimination by ion trapping
- Acid ONLY
29Considerations
- Haemodialysis
- Size lt 500 dalton
- Vd lt 1L/kg
- No/Low protein bound
- Charcoal HP
- Vd lt 1L/kg
- Affinity to Charcoal
- Exchange Transfusion
- Vd lt 1L/kg
30ToxicoDynamic
TD actions
Clinical effects
Target Site
31Target site
- Specific
- Most therapeutic drug have a specific site
- Non specific
32Specific
- Receptors
- Agonist Vs Antagonist
- Competitive Vs Non-competitive
- Ion channels
- Na, K, Ca, Cl
- Open or Close
- Enzymes
- Inhibit or Enhance
33TD action
- Dysfunction or Destruction
- Common mechanism
- Over or under of existing regulatory systems
- (ANS, Inhibitory Vs Excitatory Neurotransmitter)
- Failure to maintain bio-environment
- Failure of energy supply
- Failure of gene regulation and expression
34Receptors Site (major) Agonist Antagonist
Adrenegic a1 Vascular smooth muscles Noradrenaline Indirect Cocaine, Ampethamine Phentolamine
Adrenegic ß1 Cardiac Adrenaline Indirect Cocaine, Ampethamine ß blocker
Dopamine CNS Vascular smooth muscles Bromocriptine Indirect Cocaine, Ampethamine Antipsychotic
Serotonin CNS, Peripheral Ergots, Methamphetamine Indirect SSRI Atypical antipsychotic
Ach muscarinic CNS, ANS Pilocarpine Indirect - Cholinesterase inhibitor Atropine
Ach nicotinic CNS, skeletal muscle Nicotine Indirect - Cholinesterase inhibitor Erabutoxin (Snake Venom)
Adenosine CNS, Cardiac Vascular smooth muscles ATP Methylxanthines
Opioid CNS, viseral neurons Morphine Naloxone
GABAA CNS Indirect - Ethanol, BZO Penicillin Indirect - Flumazenil
Glycine Spinal cord, CNS Taurine Strychnine
Glutamate CNS NMDA Ketamine, Mg, Propofol
35Ion Channels Site (major) Opener Blocker
Voltage-gated Na Channel Neurons Cardiac Muscle Aconitine Ciguatoxin Na channel blocking drugs Tetrodotoxin Saxitoxin
NaK ATPase Every cell Digitalis
Potassium Channel Ikr Cardiac Sotolal QTc prolonged drugs
Ca Channel (L type) CNS, Peripheral Ca Diltiazem Verapermil Nifidipine Pb
36Enzymes Enhancer Inhibitor
Glutamic acid decarboxylase (GAD) VPA Gabapentin INH
Pyridoxine Phosphokinase (PP) INH
Cytochrome C oxidase CN, CO, H2S, Formate
Pyruvate dehydrogenase complex (PD) Thiamine Ar
Cholinesterase OP
Vit K Reductase Warfarin
? Amniolevulinic acid dehydratase(ALA) Pb
Multiples Enzymes Heavy Metals
Angiotensin Converting Enzymes (ACE) ACE I
Monoamine Oxidase (MAO) MAO I
37Non-specific Site
- Harmful thru chemical and physical properties
Mechanism Example Toxicity
Physical Effect Dry Ice Hypoxia
Physical Effect Ca oxalate Renal tubules obstruction
Electrophilic NAPQI Cell necrosis
Free radical Paraquat Lipid perioxidation
Redox Reactant Dapsone Met-Hb
Redox Reactant Ethanol Impaired gluconeogenesis
Nucleophilic Fluoride Binds Ca
38Clinical Effects
- Acute toxicity
- lt24 hours
- Subsequent toxicity
- gt24hours
- subacute chronic
39Acute
- CNS
- Too high or too low
- Seizure coma death
- Cardiopulmonary
- Arrhythmias
- Hypo/Hypertension
- Hypoxia/Hypoventilaion
- Metabolic
- Failure of energy production
- pH, e-
- Falling Apart
40Subacute Chronic
- Organ Failure
- Liver
- Renal (Pre, ATN, Post)
- Marrow
- Carcinogenesis
- Terarogenicity
41Thank You